Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 4/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 3/20 | 0.45 |
| ▸ | CHUK | O15111 | 3/20 | 0.45 |
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.45 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.45 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | PAK4 | O96013 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | PRKACA | P17612 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | LTK | P29376 | 1/20 | 0.45 |
| ▸ | GRK5 | P34947 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941331 | 1.00 | PRKCI (0.50) | PRKCIAXLALDH1A1IKBKBCHUK | |
| SCHEMBL4364193 | 0.75 | MET (0.45) | ALDH1A1KDRMETTTBK1TTBK2 | |
| SCHEMBL30213789 | 0.75 | PRKCI (0.46) | PRKCIAXLALDH1A1JAK2JAK3 | |
| SCHEMBL22941677 | 0.75 | JAK2 (0.43) | PRKCIAXLALDH1A1IKBKBCHUK | |
| SCHEMBL17495401 | 0.75 | PRKCI (0.46) | PRKCIAXLALDH1A1JAK2JAK3 | |
| SCHEMBL29486783 | 0.75 | PRKCI (0.54) | PRKCIAXLALDH1A1JAK2JAK3 | |
| SCHEMBL1935167 | 0.75 | PRKCI (0.54) | PRKCIAXLALDH1A1JAK2JAK3 | |
| SCHEMBL20774689 | 0.74 | IKBKB (0.62) | PRKCIIKBKBCHUKIGF1RDYRK1B | |
| SCHEMBL2181204 | 0.74 | MET (0.62) | AXLALDH1A1MAP2K1LRRK2MET | |
| SCHEMBL4251520 | 0.73 | MET (0.50) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115806557-B | Compounds for inhibiting apoptosis and methods of making the same | 中国科学院上海有机化学研究所 | 2025-02-14 | — | — | CN | disclosed |
| US-20240190891-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-06-13 | — | — | US | disclosed |
| EP-4182323-B1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-04-24 | — | — | EP | disclosed |
| CN-115215861-B | Aromatic heterocycle substituted alkyne compound and preparation method and application thereof | 上海翊石医药科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4182323-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-05-24 | — | — | EP | disclosed |
| CN-116075307-A | Pyridooxazine amino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115806557-A | Compound for inhibiting programmed cell death and preparation method thereof | 中国科学院上海有机化学研究所 | 2023-03-17 | — | — | CN | disclosed |
| CN-115215861-A | Aromatic heterocycle substituted alkyne compound and preparation method and application thereof | 上海翊石医药科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20040198737-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-10-07 | — | — | US | disclosed |
| US-6770643-B2 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-08-03 | — | — | US | disclosed |
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | GENELABS TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040053931-A1 | Azaindoles | AVENTIS PHARMACEUTICALS INC. | 2004-03-18 | — | — | US | disclosed |
| EP-1397360-A1 | AZAINDOLES | Aventis Pharma Limited (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-20040009983-A1 | Azaindoles | AVENTIS PHARMA LIMITED (GB) | 2004-01-15 | — | — | US | disclosed |
| WO-2003093290-A2 | NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003000688-A1 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2003-01-03 | — | — | WO | disclosed |
| EP-1263759-A2 | AZAINDOLES | Aventis Pharma Limited (GB) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001047922-A2 | AZAINDOLES | AVENTIS PHARMA LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063658-A1 | Nucleoside derivatives for treating hepatitis C virus infection | HAVCR2, PNP, NTPCR | PRKCI 1261/4885AXL 4421/4885ALDH1A1 705/4885 |
| US-20040198737-A1 | Azaindoles | CCNY, CCNO, CNKSR1 | PRKCI 770/4885AXL 558/4885ALDH1A1 4397/4885 |
| US-20040053931-A1 | Azaindoles | CDKN1A, CDK7, CDK2 | PRKCI 501/4885AXL 1258/4885ALDH1A1 939/4885 |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | PRKCI 259/4885AXL 4483/4885ALDH1A1 1538/4885 |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | PRKCI 259/4885AXL 4483/4885ALDH1A1 1538/4885 |
| US-20040009983-A1 | Azaindoles | CCNY, CCNO, CKS2 | PRKCI 1559/4885AXL 524/4885ALDH1A1 4673/4885 |
| US-20240190891-A1 | PYRIDO OXAZINE AMINO DERIVATIVES AS ALK5 INHIBITORS | TGFBR1, ACVR1, ALK | PRKCI 1497/4885AXL 133/4885ALDH1A1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.